Independent fund research. Built on SEC filings.

How we research funds

ETF · Mid-Cap · New York Life Investments

NYLI Candriam U.S. Mid Cap Equity ETF (IQSM)

Ticker IQSM · Since 2022-10-25 · · Holdings as of Jul 31, 2026

Expense ratio
0.15%$15/yr per $10k
1-yr return
+8.0%as of Dec 2025
Net assets
$329.7Mall share classes
Holdings
248

Bottom line

Is IQSM a good fund? The bottom line

IQSM is a managed mid-cap ETF from New York Life Investments.

Its expense ratio is 0.15% — about $15 a year on every $10,000 invested, cheaper than 95% of mid-cap funds we track.

It returned +8.0% over one year (as of Dec 31, 2025, per its prospectus).

With $330 million in net assets and 248 holdings, its largest position is Revolution Medicines Inc (1.3%) and the top 10 make up 9.2% of the portfolio.

What stands out

  • Low cost: cheaper than 95% of mid-cap peers
  • Broadly diversified (248 holdings)

Updated Nov 19, 2026

What IQSM invests in

The NYLIM Candriam U.S. Mid Cap Equity ETF (the Fund) seeks investment results that correspond (before fees and expenses) generally to the price and yield performance of its underlying index, the NYLIM Candriam U.S. Mid Cap Equity Index (the Underlying Index).

The Fund employs a passive management or indexing investment approach designed to track the performance of the Underlying Index. The Advisor is the index provider for the Underlying Index and Candriam serves as the index consultant to the Advisor for the Underlying Index. In its role as index consultant, Candriam assists the Advisor with the development, calculation and maintenance of the Underlying Index, including the ESG security selection process for the Underlying Index. The Underlying Index is designed to deliver exposure to equity securities of companies meeting environmental, social and corporate governance (ESG) criteria developed by Candriam and weighted using a market-capitalization weighting methodology. The Fund will, under normal circumstances, invest at least 80% of its assets (net assets, plus the amount of any borrowings for investment purposes) in the investments…

From the fund's prospectus (filed Aug 26, 2026).

IQSM performance

Fund calendar-year total returns, 2023–2025 2023: +15.8%; 2024: +9.2%; 2025: +8.0% +15.8% 2023 +9.2% 2024 +8.0% 2025
Fund gain (+)
Average annual total returns
1 yr5 yr10 yr
IQSM+8.0%——
Mid-Cap median+7.9%+8.1%+9.9%

Source: Fund prospectus, as of Dec 31, 2025

Full IQSM performance history →

What IQSM costs

On a $10,000 investment, IQSM's 0.15% expense ratio costs about $15 a year. The prospectus estimates $192 in total costs over 10 years (assuming 5% annual returns). The median mid-cap fund charges 0.88%.

See the full IQSM fee table →

IQSM top 10 holdings

#Holding% of fund
1Revolution Medicines Inc RVMD1.32%
2Twilio Inc TWLO1.01%
3Nvent Electric Plc NVT0.93%
4Burlington Stores Inc BURL0.93%
5US Foods Holding Corp USFD0.92%
6Okta Inc OKTA0.90%
7F5 Inc FFIV0.88%
8Guardant Health Inc GH0.83%
9Viatris Inc VTRS0.78%
10Mks Inc MKSI0.76%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 9.2% of the fund. See all top 25 holdings and asset mix →

Alternatives to IQSM

More funds like IQSM →

IQSM FAQ

What is the expense ratio of IQSM?
IQSM's expense ratio is 0.15%, which works out to about $15 a year for every $10,000 invested. The prospectus estimates total costs of $192 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is IQSM a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 95% of mid-cap peers; broadly diversified (248 holdings). This is general information, not personalized advice.
What does IQSM hold?
IQSM's largest holdings are Revolution Medicines Inc (1.3%), Twilio Inc (1.0%), Nvent Electric Plc (0.9%), Burlington Stores Inc (0.9%), US Foods Holding Corp (0.9%). It holds 248 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
Who manages IQSM?
IQSM is offered by New York Life Investments through New York Life Investments ETF Trust.